TBO-cell colony stimulating factor Chinese description 1

Published by on

English drug name:

Granix (Tbo-filgrastim Injection, for Subcutaneous)

Chinese drug name:

TBO-granulocyte colony-stimulating factorPrefilled syringe

Manufacturer:

Cephalon

Drug introduction

GRANIXTM (TBO-granulocyte colony-stimulating factor) injection, subcutaneous and intravenous

First US approval time: 2012 Manufacturer Cephalon:

Indications and usage

GRANIX (TBO-granulocyte colony-stimulating factor) is a patient with non-myeloid malignancies undergoing myelosuppression with feverNeutropeniaThe clinical significance of the incidence of severe neutropenia in anticancer drugs is indicative of leukocyte growth factor.

Dose and usage

Recommended dose: 5 micrograms per kilogram per day for subcutaneous injection.

Myelosuppressive chemotherapy was administered no earlier than 24 hours after the first dose was administered. Do not give chemotherapy for the first 24 hours.

Dosage form and specification

300 mcg/0.5 ml in single use prefilled syringe

480 mcg/0.8 ml single-use prefilled syringe.

Taboo

No.

Warnings and precautions

If you suspect rupture of the spleen: stop GRANIX

Acute Respiratory Distress Syndrome (ARDS): surveillance, immediate and management. Stop GRANIX if you suspect.

Allergic reactions (angiopathic edema, atopic dermatitis, drug allergies, allergies, rash, pruritic rash and urticaria)

Sickle cell crisis: A serious, sometimes fatal, sickle cell crisis may occur. Stop GRANIX if you suspect.

Adverse reactions

The most common adverse reaction to GRANIX is bone pain.

Categories: TBO-cell colony stimulating factor
Tags:

Related Posts

TBO-cell colony stimulating factor

TBO-cell colony stimulating factor Chinese description 2

General Description Tbo-filgrastim is a non-glycosylated recombinant methionyl human granulocyte colony-stimulating growth factor (r-metHuG-CSF) manufactured by recombinant DNA technology using the elite strain E. coli K802. It has a molecular weight of approximately 18.8 kDa and consists of 175 amino acids. Endogenous human G-CSF is glycosylated and has no additional methionine residues at its NH2 terminus. Mechanism of action Tbo-filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology. Tbo-filgrastim binds to G-CSF receptors and stimulates neutrophil proliferation. G-CSF is known to stimulate directional granulocyte differentiation and some terminal cell function activation, increasing neutrophil count and activity. Indications and Uses Tbo-filgrastim is a leukocyte growth factor suitable for the use of myelosuppressive anticancer drugs in patients with non-myeloid malignancies with clinically significant febrile neutropenia, reducing severe neutropenia time. (1) Dosage and administration method (1) Recommended dose: 5 μg/kg per day as a subcutaneous injection. (2) The first dose was not earlier than 24 hours after myelosuppressive chemotherapy. Do not administer within 24 hours of chemotherapy. (2.1) Dosage form and specification (1) 300 μg/0.5 mL in a single use pre-filled syringe (2) 480 μg/0.8 mL in a single use pre-filled syringe Warning and precautions (1) Spleen rupture: If you suspect termination of tbo -filgrastim (5.1) (2) Acute respiratory distress syndrome (ARDS) surveillance and immediate treatment. If you suspect termination of tbo-filgrastim (5.2) • (3) Allergic reactions (angiopathic edema, atopic dermatitis, drug hypersensitivity, hypersensitivity, rash, itching rash and urticaria) (5. 3) • (4 Sickle cell crisis: A serious and sometimes fatal crisis may occur. If you suspect that tbo-filgrastim is terminated. (5.4) Adverse reactions (1) The most common adverse reaction to tbo-filgrastim is bone pain. Used in special people Read more...

zh_CN简体中文